Finvest
CLDX Biotechnology · Clinical stage · Immunology · Single asset · Thesis updated July 2, 2026

Funded longer, still a barzolvolimab bet

01 Running thesis

Money risk fell, trial risk stayed

Celldex is now better funded. In April 2026, it raised about $323.9 million after fees and expenses. Management says cash, cash equivalents, marketable securities, and that raise should fund planned work through 2028. That matters because several major data readouts are due before then.

The bull case is simple. Barzolvolimab targets KIT on mast cells, which are immune cells that can drive hives, itching, and allergic swelling. In Phase 2 CSU, Celldex reported strong symptom control, including a 51.1% complete response rate at Week 12 in the 150 mg every 4 weeks group, versus 6.4% for placebo. If the larger Phase 3 studies confirm that profile, Celldex could have a major new immunology drug and could file a BLA, the FDA application for a biologic drug, in 2027.

The bear case is also simple. This is still mostly a one-drug company. If barzolvolimab misses in the two Phase 3 CSU studies, or if safety looks worse in a 1,939 patient program, the stock could fall hard. The April raise removed near-term financing pressure, but it did not remove the clinical risk.

The next year is busy. PN data are expected in summer 2026. CDX-622 multiple-dose and subcutaneous data are expected in Q3 2026. AD data are expected in late 2026. The biggest event remains the two Phase 3 CSU topline readouts expected in Q4 2026.

May 2026Celldex reported about $323.9 million of net proceeds from an April 2026 stock offering. Management now says planned cash runway extends through 2028, which lowers financing risk before the 2026 data readouts.
Feb 2026The 2025 annual filing confirmed enrollment completion for the Phase 3 CSU trials and Phase 2 PN and AD studies. That made the second half of 2026 catalyst calendar clearer.
Nov 2025The initial thesis centered on barzolvolimab as the main asset. The same filing history also showed the EoE program had been stopped, keeping the single-asset risk front and center.
02 Business model

No sales yet, value in trials

Celldex does not sell an approved drug today. It spends money to discover and test antibody medicines, then aims to get them approved, partner them, or sell them itself. Small contract and grant revenues exist, but product sales are not funding the business.

Most spending goes into barzolvolimab. In Q1 2026, Celldex reported $73.0 million of total R&D expense, with $62.2 million tied to the Barzolvolimab/Anti-KIT program. That shows how much the company is leaning into this one lead drug.

The hoped-for edge is intellectual property and know-how around mast-cell biology. If barzolvolimab is approved, Celldex wants the option to become a commercial company. If the launch cost or market fight looks too heavy, a partnership could be the cleaner path.

The model breaks if trials do not support approval. Without product revenue, Celldex has no steady cash engine to absorb a major clinical setback. The cash runway through 2028 gives it time, but not proof.

03 Product portfolio

One lead antibody, several shots

Growth engine

Barzolvolimab in CSU

This is the core program. Two global Phase 3 CSU trials completed enrollment in February 2026, and topline data are expected in Q4 2026.

Option

Barzolvolimab in CIndU

A global Phase 3 study in cold urticaria and symptomatic dermographism began in December 2025. It could extend the drug into trigger-based hives if CSU works.

Option

Barzolvolimab in PN

The Phase 2 prurigo nodularis trial completed enrollment in December 2025. Topline data are expected in summer 2026.

Option

Barzolvolimab in AD

The Phase 2 atopic dermatitis trial completed enrollment in January 2026. Data are expected in late 2026, and the bar for moving into Phase 3 is still an open question.

Option

CDX-622

CDX-622 is a bispecific antibody aimed at TSLP and mast-cell survival. It is in Phase 1 testing, with multiple-dose and subcutaneous data expected in Q3 2026.

Option

EoE program

Celldex stopped barzolvolimab development in eosinophilic esophagitis in August 2025. The miss is a reminder that mast-cell depletion may not translate into every disease.

04 Business segments

R&D dollars show the focus

Barzolvolimab/Anti-KIT R&D85%growing fast
CDX-622 R&D6%declining
Other R&D9%declining

Celldex reports one operating segment and no product sales. The mix below uses Q1 2026 R&D expense by program from MD&A, so it is a spending mix, not a revenue mix.

05 Risk factors

What could break the story

Phase 3 CSU miss

High impact · Medium odds

The main value driver is the two Phase 3 CSU trials. Earlier CSU data were strong, but larger studies can fail even after good Phase 2 results. A weak efficacy result would likely reset the whole investment case.

We watchQ4 2026 topline data from EMBARQ-CSU1 and EMBARQ-CSU2, especially UAS7 response and complete-control rates.

Safety surprise from mast-cell targeting

High impact · Medium odds

Barzolvolimab is designed to reduce mast cells by blocking KIT. That may help disease, but investors need to watch blood counts, infections, and other immune effects as exposure grows. A new safety imbalance in Phase 3 could limit dosing, labeling, or approval odds.

We watchPhase 3 adverse event tables, with focus on neutropenia, ANC decreases, infections, and discontinuations.

Regulatory delay after positive data

High impact · Medium odds

Even strong trial results do not guarantee FDA approval. Celldex plans a 2027 BLA filing if Phase 3 CSU data are positive. Questions on safety follow-up, manufacturing, or trial design could slow the filing or review.

We watchManagement updates on the 2027 BLA plan, FDA meeting feedback, and any request for more clinical data.

PN and AD fail to broaden the drug

Medium impact · Medium odds

PN and AD could make barzolvolimab much more valuable. They could also show that the mechanism works best in urticaria and not in broader skin disease. That would not kill the CSU case, but it would narrow the upside.

We watchTopline PN data in summer 2026 and AD data in late 2026, plus whether Celldex commits to Phase 3 studies.

Commercial plan is not ready

Medium impact · Medium odds

Celldex wants the option to become a commercial-stage company. That takes sales teams, payer work, medical education, and supply planning. If the company waits too long to show a clear launch plan, investors may worry that approval would not quickly turn into sales.

We watchUpdates on hiring, launch spend, payer access plans, and whether Celldex seeks a commercial partner.
06 Quick answers

In one breath

What does Celldex Therapeutics do?

Celldex develops antibody drugs for allergic, inflammatory, and autoimmune diseases. Its main drug is barzolvolimab, which targets KIT on mast cells.

Does Celldex have product revenue?

No. Celldex has no approved drug sales today, so it funds its work with cash on hand, equity raises, and possible future partnerships.

What is the biggest Celldex catalyst in 2026?

The biggest catalyst is topline data from the two Phase 3 CSU studies, expected in Q4 2026. PN, AD, and CDX-622 data are also expected before or around that window.

Why did the April 2026 financing matter?

Celldex raised about $323.9 million in net proceeds. Management says that extends planned runway through 2028, which lowers near-term financing risk before the key data readouts.